Reaction phenotyping research is primarily used to identify the enzymes responsible for the biotransformation of compounds. BOC Sciences can provide in vitro reaction phenotyping research that meets regulatory expectations, including CYP enzymes, non-CYP enzymes, and conjugated enzymes. Our reaction phenotyping characterization provides metabolic data information for the sample to be tested, which can be used to assess victim DDI potential and provide useful information for clinical study design.
In preclinical studies of new drugs, the metabolic enzyme phenotypes of drugs should be identified and the elimination ratios of their major metabolic enzymes should be obtained to provide important information for drug-drug interaction studies.
CYP450 is a superfamily of heme-containing proteins that widely exists in humans and mammals, and is mainly involved in the oxidative metabolism of drugs, environmental compounds and endogenous substances. CYP450 is the predominant metabolic enzyme in the human body, and about 60% of drug metabolism is mainly mediated by the CYP450 enzyme family. Based on the importance of the relevant enzyme isoforms in drug metabolism, CYP450 can be classified into the following three categories:
Currently, three methods are used to identify the enzyme phenotype of CYP450: selective inhibition, recombinant human CYP450 isozyme assay, and correlation analysis.
UGT is a class of membrane proteins located in the endoplasmic reticulum inner membrane that catalyzes the removal and transfer of glucuronide from uridine diphosphate glucuronide to receptor molecules to generate glucuronide conjugates for receptor molecules. UGT plays an important role in drug metabolism in humans, second only to CYP450.
UGT enzyme family can also be divided into several families and subfamilies. The UGT enzymes involved in the metabolism of exogenous substances mainly belong to the UGT1A and UGT2B subfamilies, including UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7 and UGT2B15. Unlike the CYP450 enzyme family, the identification of the enzyme phenotypes of the UGT enzyme family is limited by many factors, and a more mature research system has not yet been developed.
Reaction phenotyping of CYP and UGT | |
Test Concentration | 5 μM (different concentrations available) |
Enzymes | CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7 and UGT2B15 (others available upon request) |
Time Point | 0, 5, 15, 30, 45, 60, 120 minutes |
Number of Repetitions | n=3 per time point |
Negative Control | cDNA expression control preparation (no CYP450 or UGT enzymes present) |
Positive Control | Known probe substrate |
Test Article Requirements | Depends on the number of isoforms requested. |
Analytical Method | LC-MS/MS |
We offer a wide range of services from screening to reporting, making it a convenient one-stop shop for customers. Multiple automated instrument platforms enable continuous throughput improvement.
Relying on strong technical capabilities, excellent operational services and constantly improving experimental throughput, we can save time and cost for our customers.
The introduction of an automated platform can reduce human errors, reduce experimental errors and improve data quality.
Our team of experts has extensive experience in ADME studies, providing the most effective data in the shortest possible time, saving resources and accelerating the development process for drug discovery projects.